Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hirsh

Showing results (111-120 of 2,959) with videos related to

Pageof 296
Sort By:
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
From unfractionated heparins to low molecular weight heparinsJ Hirsh
Clinical Lung Cancer|July 28, 2009
Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancerVera Hirsh
Thrombosis and Haemostasis|April 23, 1979
International committee communications. Diagnosis of venous thrombosisJ Hirsh
Brain Research|August 17, 1973
The effect of septal input upon hippocampal unit response in normal conditions in ratsR Hirsh
Clinical Lung Cancer|September 3, 2011
Emerging safety data for bevacizumab in advanced non-small-cell lung cancerVera Hirsh
Anti-Cancer Agents in Medicinal Chemistry|February 15, 2012
Emerging anticancer effects of antiresorptive therapiesVera Hirsh
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?Vera Hirsh
Current Oncology (Toronto, Ont.)|June 10, 2011
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancerV Hirsh
Circulation|October 14, 1998
Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable anginaJ Hirsh
Current Opinion in Hematology|October 17, 1998
Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparinsJ Hirsh
Pageof 296

Showing results (111-120 of 2,959) with videos related to

Sort By:
Pageof 296
Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
From unfractionated heparins to low molecular weight heparinsJ Hirsh
Clinical Lung Cancer|July 28, 2009
Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancerVera Hirsh
Thrombosis and Haemostasis|April 23, 1979
International committee communications. Diagnosis of venous thrombosisJ Hirsh
Brain Research|August 17, 1973
The effect of septal input upon hippocampal unit response in normal conditions in ratsR Hirsh
Clinical Lung Cancer|September 3, 2011
Emerging safety data for bevacizumab in advanced non-small-cell lung cancerVera Hirsh
Anti-Cancer Agents in Medicinal Chemistry|February 15, 2012
Emerging anticancer effects of antiresorptive therapiesVera Hirsh
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?Vera Hirsh
Current Oncology (Toronto, Ont.)|June 10, 2011
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancerV Hirsh
Circulation|October 14, 1998
Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable anginaJ Hirsh
Current Opinion in Hematology|October 17, 1998
Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparinsJ Hirsh
Pageof 296